



**Contact:**

Dr. Misha Plam

President & CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

**Daniel M. Bradbury joins the Business Advisory Board of AmideBio, LLC**

**BOULDER, CO, November 21, 2013** – AmideBio, LLC, a privately held biopharmaceutical company which has leveraged its novel processes for the manufacturing of peptides and proteins to generate a pipeline of therapeutics including a novel Thermostable Insulin, announced today that Daniel M. Bradbury has joined AmideBio's Business Advisory Board. Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm in La Jolla, California and formerly, the President and Chief Executive Officer of Amylin Pharmaceuticals, Inc.

"I am thrilled to have a person of Mr. Bradbury's caliber as part of AmideBio's advisory board," said Dr. Misha Plam, AmideBio's President and CEO. "His experience as CEO of Amylin guiding the development and commercialization of multiple novel treatments for diabetes will be invaluable to AmideBio as we build our pipeline and cultivate new relationships with pharma partners." Dr. Plam added, "I am confident Mr. Bradbury's strategic insights will contribute to AmideBio's near term and future successes.

"I am excited to join the AmideBio Business Advisory Board and to have the opportunity to assist management in creating and implementing strategies that will bring life changing medicines to patients with metabolic disorders," said Mr. Bradbury.

Mr. Bradbury's distinguished career in the pharmaceutical industry spans nearly 30 years. During his 18-year tenure at Amylin, the company launched three first-in-class medicines: Symlin, Byetta and Bydureon, the only once-a-week therapy to treat diabetes. He served as Amylin's Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb for \$7 billion in August 2012. Before joining Amylin, Mr. Bradbury held marketing and sales positions for ten years at SmithKline Beecham Pharmaceuticals.

As a much sought after industry expert, Mr. Bradbury currently serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private), Microdermis, Inc. (Private) and Profil Institute for Clinical Research (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego's Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

**About AmideBio:**

AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides and build a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach, results in fewer batch inconsistencies and less waste generation. Such advantages offer AmideBio multiple opportunities to offer technology and cost benefits to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

- ENDS -